[摘要] 目的：观察乌司他丁与氢化可的松联用治疗对脓毒症患者的影响。方

[Abstract] Objective: To observe the effect of combined use of ulinastatin and hydrocortisone on patients with sepsis. Methods: The 65 sepsis patients admitted to our hospital from March 2016 to October 2019 were randomly divided into a reference group (32 cases) and a combined group (33 cases). The reference group was added with hydrogenation on the basis of conventional treatment. In the combination group, ulinastatin was combined with hydrocortisone. The levels and clinical efficacy of tumor necrosis factor (TNF-α), interleukin-10 (IL-10) were compared between the two groups. Results: After treatment, the levels of IL-10 and TNF-α in the two groups were significantly lower than before treatment (both P <0.05), and the combined group [TNF-α (7.21 ± 1.09) pg / mL, IL-10 (11.35 ± 3.91) pg / mL] was significantly lower than that of the reference group (all P <0.05); the clinical efficacy (90.91%) of the combined group was significantly higher than that of the reference group (65.63%) (P <0.05). Conclusion: The combination of ulinastatin and hydrocortisone in the treatment of sepsis can significantly reduce the level of inflammatory factors and improve the clinical efficacy of patients.

[摘要] 目的：观察乌司他丁与氢化可的松联用治疗对脓毒症患者的影响。方法：将2016年3月~2019年10月本院收治的65脓毒症患者随机分为参照组（32例）和联合组（33例），参照组在常规治疗的基础上加用氢化可的松治疗，联合组将乌司他丁与氢化可的松联用治疗。比较两组肿瘤坏死因子（TNF-α）、白细胞介素-10（IL-10）水平及临床疗效。结果：治疗后，两组IL-10、TNF-α水平均较治疗前显著降低（均P＜0.05），且联合组[TNF-α（7.21±1.09）pg/mL、 IL-10（11.35±3.91）pg/mL]显著低于参照组 （均P＜0.05）；联合组临床疗效（90.91%）显著高于参照组（65.63%）（P＜0.05）。结论：联合乌司他丁与氢化可的松治疗脓毒症可显著降低患者炎症因子水平，提高临床疗效。

[Abstract] Objective: To observe the effect of ulinastatin combined with hydrocortisone on sepsis. Methods: 65 patients with sepsis admitted to our hospital from March 2016 to October 2019 were randomly divided into the reference group (32 cases) and the combined group (33 cases). The reference group was treated with hydrocortisone on the basis of conventional treatment, and the combined group was treated with Ulinastatin and hydrocortisone. The levels of TNF - α and IL-10 in the two groups were compared. Results: after treatment, the levels of IL-10 and TNF - α in the two groups were significantly lower than those before treatment (P < 0.05), and the levels of TNF - α (7.21 ± 1.09) pg / ml and IL-10 (11.35 ± 3.91) pg / ml in the combined group were significantly lower than those in the reference group (P < 0.05), and the clinical efficacy in the combined group (90.91%) was significantly higher than that in the reference group (65.63%) (P < 0.05). Conclusion: the combination of ulinastatin and hydrocortisone in the treatment of sepsis can significantly reduce the level of inflammatory factors and improve the clinical efficacy.<br>